Spironolactone for hypertension

Cochrane Database of Systematic Reviews

Volumn , Issue 4, 2009, Pages

  Tejani, Aaron M ^a   Fowkes, Curt T ^b   Batterink, Josh ^b  

^a FRASER HEALTH AUTHORITY   (Canada)

^b Northern Health Authority   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; SPIRONOLACTONE;

CLINICAL PROTOCOL; CLINICAL RESEARCH; CLINICAL TRIAL; DRUG RESEARCH; HUMAN; HYPERTENSION; MONOTHERAPY; MORBIDITY; MORTALITY; REVIEW;

EID: 77950178322     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD008169     Document Type: Review

References (10)

1. Brunton 2006 Brunton LL, Lazo JS, Parker KL. Goodman & Gilmans: The pharmacological basis of therapeutics. 11th Edition. New York: McGraw-Hill, 2006.
2. CHEP 2008 Canadian Hypertension Education Program (CHEP). The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension. Canadian Journal of Cardiology 2008;24(6):455-475.
3. Chobanian 2003 Chobanian AV, Bakris GL, Black HR, et al.Seventh report of the Joint National Committee on Prevention, Detection,Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42: 1206-52.
4. Connell 2008 Connell JM, MacKenzie SM, Freel EM, Fraser R, Davies E. A Lifetime of Aldosterone Excess: Long-Term Consequences of Altered Regulation of Aldosterone Production for Cardiovascular Function. Endocrine Reviews 2008;29:133-154.
5. Cranston 1962 Cranston WI, Juel-Jensen BE. The effects of spironolactone and chlorthalidone on arterial pressure. Lancet 1962;279:1161-1164.
6. Jeunemaitre 1987 Jeunemaitre X, Chatellier G, Kreft-Jais C, Charru A, Devries C, Plouin PF, Corvol P, Menard J. Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol 1987;60: 820-825.
7. Jurrlink 2004 Jurrlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, Redelmeier DA. Rates of hyperkalemia after publication of the randomized aldactone evaluation study. N Eng J Med 2004;351:543- 551.
8. Pitt 1999 Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341:709-717.
9. WHO 2003 World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/ International Society of Hypertension (ISH) statement on management of hypertension. Journal of Hypertension 2003;21: 1983-1992.
10. Williams 2004 Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, Sever PS, Thom S. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV.. J Hum Hypertens 2004;18:139-185.